ストックスクリーナーアプリを入手
1.39
0.71%
-0.01
アフターアワーズ：
1.40
0.01
+0.72%
Citius Oncology Inc (CTOR) 最新ニュース
Citius Oncology (NASDAQ:CTOR) Stock Quotes, Forecast and News Summary - Benzinga
CTMX stock rated an Overweight by Piper Sandler - Knox Daily
CTOR Stock Update: Citius Oncology Inc.’s Banking’s Market Struggles and Potential Opportunities - The InvestChronicle
Investor’s Delight: Cytek BioSciences Inc (CTKB) Closes Strong at 5.19, Up 1.96 - The Dwinnex
Cytek BioSciences Inc (CTKB)’s stock performance: a year in review - US Post News
Check Out Citius Pharmaceuticals Inc (CTXR)’s Trade Data Rather Than the Analysts’ Views - SETE News
CTXR’s price-to-book ratio: An indicator of the company’s performance - US Post News
Ciena Stock Goes to Buy From Sell at Citi. Here’s Why. - Barron's
Closing Strong: Citius Oncology Inc. (CTOR) Ends at 1.60, Down -4.19 from Last Close - The Dwinnex
XTX Topco Ltd Acquires 15,997 Shares of Catalent, Inc. (NYSE:CTLT) - Defense World
CTOR stock touches 52-week low at $1.51 amid market challenges - Investing.com Canada
CitiusTech to pursue acquisitions, shifts hiring strategy on GenAI push - TechCircle
Citius Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement - Quantisnow
NCCN Adds Denileukin Diftitox to CTCL Clinical Practice Guidelines in Oncology - OncLive
Citius Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investment Conference - Kilgore News Herald
Citius Pharmaceuticals, Inc. and Citius Oncology, Inc. Announce LYMPHIR™ (Denileukin Diftitox-cxdl) Added to National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology - Nasdaq
Citius Pharmaceuticals Announces Closing of $15 Million Registered Direct Offering - Quantisnow
Citius Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investment Conference - StockTitan
A stock that deserves closer examination: Citius Oncology Inc. (CTOR) - US Post News
Daily Market Movement: Citius Oncology Inc. (CTOR)’s financial ratios: A comprehensive overview - The Dwinnex
CTOR stock touches 52-week low at $1.67 amid market challenges - Investing.com
Citius Oncology Inc. (CTOR) requires closer examination - US Post News
Citius Pharmaceuticals selloff since spinout an opportunity, says EF Hutton - TipRanks
CTOR’s Market Whiplash: -81.72% YTD Decline, -82.47% Plunge in 30 Days - The InvestChronicle
Closing Bell Recap: Citius Oncology Inc. (CTOR) Ends at 2.00, Reflecting a -11.11 Downturn - The Dwinnex
Citius Oncology Inc. completes strategic acquisition By Investing.com - Investing.com Australia
Citius Oncology Inc. completes strategic acquisition - Investing.com
Citius Oncology Inc. completes strategic acquisition By Investing.com - Investing.com UK
Citius Pharma finalizes $675M oncology unit spinoff - NJBIZ
Closing Bell Recap: Citius Oncology Inc. (CTOR) Ends at 2.47, Reflecting a -22.81 Downturn - The Dwinnex
Citius merges oncology subsidiary with TenX Keane - Yahoo Finance
Citius merges oncology subsidiary with TenX Keane - Pharmaceutical Technology
Citius Pharmaceuticals Completes Merger of Subsidiary with TenX Keane to form Citius Oncology - citybiz
Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2024 Financial Results and Provides Business Update - The Malaysian Reserve
Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2024 Financial Results and Provides Business Update - Kilgore News Herald
Citius Pharmaceuticals Completes Merger of Subsidiary with TenX Keane to form Citius Oncology, Inc. - Yahoo Finance
Citius Pharmaceuticals Completes Merger of Subsidiary with TenX Keane to form Citius Oncology, Inc. - Kilgore News Herald
Citius Pharmaceuticals to Host Investor Call to Discuss Recent and Upcoming Developments - Quantisnow
CTORCitius Oncology, Inc. Latest Stock News & Market Updates - StockTitan
TenX Keane Acquisition Addresses Trading Halt, Continues Towards Closing of Business Combination, and Provides Market Update - ForexTV.com
TenX Keane Acquisition Addresses Trading Halt, Continues Towards Closing of Business Combination, and Provides Market Update - StockTitan
TenX Keane addresses trading halt, continues toward combination closing - TipRanks
New Ontak on track as Citius wins FDA’s nod for Lymphir in CTCL - BioWorld Online
US FDA approves Citius' therapy for rare blood cancer - Reuters.com
Citius Pharmaceuticals Receives FDA Approval for LYMPHIR™ (denileukin diftitox-cxdl) Immunotherapy for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell Lymphoma - PR Newswire
Biotech Alert: Searches spiking for these stocks today - TipRanks
Citius Pharmaceuticals Advances Oncology Spinoff Through Merger with TenX Keane - Vancity Buzz
Citius Pharmaceuticals To Receive 65 Million Shares Of TenX Keane For Merger Of Citius Oncology - Nasdaq
Citius Pharma secures majority in TenX merger deal - Investing.com India
Citius Pharma secures majority in TenX merger deal By Investing.com - Investing.com Australia
Citius Pharma secures majority in TenX merger deal By Investing.com - Investing.com Canada
TenX Keane Acquisition Shareholders Approve Previously Announced Merger to Form Citius Oncology, Inc., a Publicly Listed Subsidiary of Citius Pharmaceuticals - StockTitan
TenX Keane Acquisition stock soars to all-time high of $18.19 - Investing.com
Citius Pharmaceuticals Poised for Major Market Breakthroughs with Two Leading Products - Vancity Buzz
Citius Pharmaceuticals Nears Market Breakthrough With Two Leading Products - WICZ
When Will Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) Turn A Profit? - Yahoo Finance
TenX Keane Acquisition extends merger timeline with Citius Pharma - Investing.com
Citius Pharmaceuticals initiated with a Buy at EF Hutton - TipRanks
Citius Pharmaceuticals (CTXR) Nears Key FDA Decisions and Launch Plans for 2024 - News Channel Nebraska
Citius Pharmaceuticals Details Near-Term Milestones for Late-Stage Candidates - StockTitan
Citius Pharmaceuticals to Host Investor Call to Discuss Topline Results of Phase 3 Trial of Mino-Lok Antibiotic Lock Solution - Yahoo Finance
0.10%
大文字化:
|
ボリューム (24 時間):